CAJ | 학술논문

处于骨量减少期的绝经后妇女相对于骨质疏松患者同样有较大的骨折风险,判断这类人群是否需要使用药物干预治疗的适用标准不应仅根据骨密度,还应同时结合存在的骨折风险因素等综合考虑.二膦酸盐类、选择性雌激素受体调节剂、雷尼酸锶盐等多种药物在这一人群中的应用可以提高骨密度、降低骨折风险.
처우골량감소기적절경후부녀상대우골질소송환자동양유교대적골절풍험,판단저류인군시부수요사용약물간예치료적괄용표준불응부근거골밀도,환응동시결합존재적골절풍험인소등종합고필.이련산염류、선택성자격소수체조절제、뢰니산송염등다충약물재저일인군중적응용가이제고골밀도、강저골절풍험.
Postmenopausal women with osteopenia comparing with osteoporosis also has high risk of fractures.Among this group of people,the criteria for initiation of intervention with pharmacotherapy is not merely according to bone mineral density(BMD),but considering of risk factors for fractures.Various medicines such as bisphosphonate,selective estrogen receptor modulator,strontium ranelate can increase BMD and decrease the risk of fractures in this crowd.